SCHEMBL7180997

SCHEMBL7180997

CCOC(=O)C(C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F)c1ccccc1.O=[PH3]

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.50
EPHX2 P34913 4/20 0.43
PPARG P37231 3/20 0.43
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.39
KDM4E B2RXH2 2/20 0.38
TAS2R14 Q9NYV8 1/20 0.38
PIN1 Q13526 1/20 0.38
TXNRD1 Q16881 1/20 0.37
KCNK3 O14649 1/20 0.37
KCNK9 Q9NPC2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177281 0.90 MMP8 (0.39) MMP8EPHX2PPARGTSHRTXNRD1
SCHEMBL7175411 0.90 KMT2A (0.44) MMP8EPHX2PPARGMEN1KMT2A
SCHEMBL7179970 0.88 POLB (0.43) NPC1TSHRALDH1A1SMN1; SMN2
SCHEMBL7188763 0.88 ALDH1A1 (0.41) MMP8EPHX2PPARGMEN1KMT2A
SCHEMBL7180754 0.87 NPC1 (0.43) NPC1TSHRALDH1A1SMN1; SMN2
SCHEMBL7181516 0.86 TXNRD1 (0.41) PPARGKMT2ATXNRD1ALDH1A1
SCHEMBL7176991 0.86 LMNA (0.44) NPC1TSHRALDH1A1SMN1; SMN2
SCHEMBL7189969 0.86 LMNA (0.44) NPC1TSHRALDH1A1SMN1; SMN2
SCHEMBL7186876 0.86 LMNA (0.44) NPC1TSHRALDH1A1SMN1; SMN2
SCHEMBL7186478 0.86 LMNA (0.44) NPC1TSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MMP8 4586/4885EPHX2 2048/4885PPARG 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.